How is denosumab administered by injection?
Feb 25, 2023
Source: Cainiu Health
Dr. Liu Aihua
Introduction
Denosumab refers to denosumab injection, which must be administered subcutaneously with the assistance of a physician. The main active ingredient of denosumab injection is immunoglobulin G2 monoclonal antibody, which can prevent the activation of osteoclasts and inhibit tumor metastasis. It is commonly used for the treatment of giant cell tumor of bone that cannot be surgically removed or that causes severe functional impairment following surgical resection.
Denosumab refers to denosumab injection, which should be administered subcutaneously with the assistance of a physician.
The main active ingredient in denosumab injection is immunoglobulin G2 monoclonal antibody, which prevents osteoclast activation and inhibits tumor metastasis. It is commonly used to treat giant cell tumor of bone that cannot be surgically removed or cases where surgery would result in severe functional impairment. It is also used to prevent bone metastasis in multiple myeloma and solid tumors. Denosumab injection is administered via subcutaneous injection. Before administration, remove the medication from refrigeration and allow it to sit at room temperature for approximately 20 minutes. Inject the appropriate dose subcutaneously into the upper arm, thigh, or abdomen; intramuscular or intravenous injection must not be used.
To avoid injecting into the muscle layer when administering subcutaneous injections of denosumab, it is recommended to insert the needle at a slight angle into the skin. After the first injection, patients are advised to be observed for 2–3 hours to monitor for adverse reactions such as nausea, headache, or limb pain. Any abnormal symptoms should be reported to a doctor promptly. In daily life, adequate rest is important, along with maintaining a positive and optimistic mindset and building confidence in overcoming the disease.
